-36%

est. 2Y upside i

HealthcareAI & MLSeries B

Rank

#884

Sector

Healthtech, AI, Patient Experience

Est. Liquidity

~3Y

Data Quality

Data: High

Vital presents a unique equity opportunity due to its extremely low current valuation ($54M) relative to its substantial revenue ($85M) and high growth (90% YoY) in a large, underserved market.

Last updated: March 10, 2026

Bull (29%)+300%

Vital leverages its proprietary AI platform and deep EHR integrations to become a dominant player in patient experience, expanding its customer base and product offerings. Revenue grows significantly to $300M+ by 2028, and the market re-rates its valuation to $216M (4x current revenue), representing a 300% increase. However, due to the $46M liquidation preference, common stock holders would see a return on $170M ($216M - $46M), representing a 2025% return on their effective initial common equity.

Base (46%)+50%

Vital maintains its strong growth trajectory, expanding its customer base and solidifying its position in patient experience. Revenue reaches $200M by 2028, and the company is valued at $81M, representing a 50% increase from the current valuation. After accounting for the $46M liquidation preference, common stock holders would see a return on $35M ($81M - $46M), which is a 337.5% return on the initial $8M common equity.

Bear (25%)-70%

Increased competition from incumbents like Epic and Cerner, or a slowdown in hospital IT spending, causes Vital's growth to stall. The company is acquired for $16.2M, representing a 70% decrease in valuation. Given the $46M liquidation preference, common stock holders would receive nothing, resulting in a -100% return.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

85%

Investors hold approximately $46M in liquidation preferences, which is 85.19% of the current $54M valuation, significantly ahead of common stock holders. In an exit below $46M, common stock holders receive nothing.

Dilution Risk

high

With $46M raised on a $54M valuation, future funding rounds are likely to cause significant further dilution to common shareholders, especially if the valuation does not substantially increase.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Vital's shares at this stage.

Other — 2 roles

View all 2 open roles at Vital →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Vital's data — designed to show you've done your homework.

  • 1

    “Given the significant incumbent presence of Epic and Cerner in hospital IT, how does Vital plan to expand its market penetration beyond integrating with existing EHR systems, and what are the long-term strategies to prevent incumbents from replicating Vital's AI-powered patient experience layer?”

  • 2

    “With $85M in revenue and 90% YoY growth, the current $54M valuation (0.63x P/S) appears unusually low. Can you elaborate on the factors contributing to this valuation estimate and how the company plans to address any underlying concerns that might be reflected in this multiple?”

  • 3

    “Considering the $46M in total funding and the current $54M valuation, what is the company's strategy for managing future dilution, and what is the anticipated timeline and preferred exit path (e.g., IPO, acquisition) to provide liquidity for employees?”

Community

Valuation Sentiment

Our model estimates -36% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.